Bacterial endocarditis is a serious and potentially life-threatening infection of the inner lining of the heart chambers (endocardium) or heart valves. It occurs when bacteria enter the bloodstream and attach to damaged areas of the heart, forming infective masses known as vegetations. Common causative bacteria include Streptococcus and Staphylococcus species. Individuals with pre-existing heart conditions, such as damaged heart valves or congenital heart defects, are at an increased risk of developing bacterial endocarditis. The condition often presents with symptoms like fever, fatigue, chills, and heart murmurs. Diagnosis involves blood cultures and imaging studies like echocardiography. Bacterial endocarditis requires prompt and targeted antibiotic treatment to eliminate the infecting bacteria. In severe cases or when complications arise, surgical intervention may be necessary to repair or replace damaged heart valves. Preventive measures involve antibiotic prophylaxis before certain dental or medical procedures in individuals with high-risk conditions. However, recommendations for prophylaxis have evolved, and the decision is often based on individual patient factors. Timely diagnosis and appropriate management are crucial to improving outcomes and reducing the risk of complications associated with bacterial endocarditis.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States